Localization of fibrinolytic activators and inhibitors in normal and atherosclerotic vessels

Thrombosis and Haemostasis

Volumn 75, Issue 6, 1996, Pages 933-938

  Falkenberg, Mårten ^a,b   Tjärnström, Johan ^a   Örtenwall, Per ^a   Olausson, Michael ^b   Risberg, Bo ^c  

^a Östra ^*  (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ADVENTITIA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VASA VASORUM; VASCULAR ENDOTHELIUM;

EID: 0029953410     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650397     Document Type: Article

References (29)

1. Sprenglers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
2. Ranby M, Bergsdorf N, Nilsson T. Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 1982; 27: 175-83.
3. Todd AS. The histological localization of fibrinolysin activator. J Pathol Bad 1959; 78: 281-283.
4. Danø K, Andreasen JA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-239.
5. Estreicher A, Wohlwend A, Belin D, Schleuning W-D, Vassalli J-D. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989; 264: 1180-9.
6. van Hinsberg VW, van der Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-8.
7. Craig H, Lundgren MD, Hirofumi Sawa MD, Burton E, Sobel MD, Satoshi Fuji MD. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy. Circulation 1994; 90: 1927-34.
8. Vassalli JD, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
9. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 1991; 34: 179-92.
10. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff J. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Prot Natl Acad Sci USA 1992; 89: 6998-7002.
11. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138-43.
12. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F. Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
13. Chomiki N, Henry M, Alessi MC, Anfonsso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72: 44-53.
14. Cordell JL, Falini B, Erber WN,Ghosh AK, Abdulazis Z, MacDonald S, Pulford KAF, Stein H, Mason DY. Immunoenzymatic labeling of mono-clonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-29.
15. Buø L, Lynberg T, Jørgensen L. Johansen H, Aasen AO. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenrcarcinomas. APMIS 1993; 101: 235-41.
16. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Eng J Med 1985; 313: 1557-63.
17. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
18. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar W, Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vase Biol 1995; 15: 1444-55.
19. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vase Biol 1995; 15: 1432-43.
20. Horie T, Sekigushi M, Hirosawa K. Coronary thrombosis in pathogenesis of acute myocardial infarction: Histopathological study of 108 necropsied cases using serial section. Br Heart J 1978; 40: 153.
21. Falk E. Plaque rupture with severe preexisting stenosis precipitating coronary thrombosis: Characteristics of coronary atherosclerolic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 127.
22. Amman V, Nilsson A, Stemme S, Risberg B, Ryroo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb Res 1994; 76: 487-99.
23. Jakobsson A. Induction and inhibition of experimental angiogenesis. Thesis. Vasastadens Bokbinderi AB, Göteborg. 1994.
24. Reilly CF, MacFall RC. Platelet-derived growth factor and transforming growth factor B (beta) regulate plasminogen activator inhibitor 1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266: 9419-27.
25. Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenisis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-7.
26. Gown A, TsukadaT, Ross R, Human atherosclerosis: II: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 1986; 125: 191-207.
27. Nathan CF, Secretory products of macrophages. J Clin Invest 1987; 79: 319-26.
28. Schleef RR, Bevilacqua MP, Sawdey M Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular cndothelium. J Biol Chem 1988; 263: 5797-803.
29. Amman V, Stemme S, Rymo L, Risberg B. Interferon-γ modulates the fibrinolytic response in cultured human endothelial cells. Thromb Res 1995; 77: 431-40.